Unicycive Therapeutics, Inc
  • About
    • Our Story
    • Our Focus
    • Our Team
    • Board of Directors
  • Our Science
    • Our Approach
    • Pipeline
    • Oxylanthanum Carbonate (OLC)
    • UNI-494
    • Publications & Press
  • Investors
  • Contact
    • Careers

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Mar 06, 2023 7:00am EST

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

Feb 27, 2023 7:00am EST

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

Feb 02, 2023 8:30am EST

Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

Jan 23, 2023 7:00am EST

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

Jan 05, 2023 7:00am EST

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

Dec 29, 2022 11:31am EST

Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock

Dec 28, 2022 8:30am EST

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

Dec 22, 2022 7:00am EST

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

Nov 28, 2022 7:00am EST

Unicycive to Participate in Upcoming Investor Conferences

Nov 21, 2022 7:00am EST

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

  • arrow_back
  • 1…
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Unicycive Theraputics, Inc

About
Our story
Our focus
Our team
Boards of Directors

Our Science
Our Approach
Therapeutic Pipeline
OLC
UNI-494
Publications & Press

Investors

Contact
Careers

4300 El Camino Real, Suite #210
Los Altos, CA 94022
+1 (650) 351-4495
info@unicycive.com

  • LinkedIn
  • YouTube
  • Facebook
  • Instagram
  • Twitter

Copyright © 2025 Unicycive

Legal Notices and Terms of Use Privacy Policy Ad and Cookie Policy